Inhalation drug delivery continues to evolve and develop for the delivery of novel compounds. In a recent publication, Lovelace Biomedical supported TFF Pharmaceuticals with their thin film freezing technology for delivery of an mAb against SARS-CoV2. These technologies, along with validated animal models, enable non-clinical evaluation of dry powder mAb’s.
If you are interested in how to evaluate your formulation reach out to Lovelace Biomedical.